PD-1 blockade overcomes adaptive immune resistance in treatment with anchored-GM-CSF bladder cancer cells vaccine

6Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Purpose: To investigate whether PD-L1 mediated adaptive resistance could occur in treatment with Anchored-GM-CSF vaccine and whether PD-1 blockade combined with Anchored-GM-CSF vaccine could induce a greater anti-tumor immune response than either immunotherapy alone. Materials and Methods: After establishing long-established subcutaneous metastasis bladder cancer models, mice were treated with Anchored-GM-CSF vaccine and/or anti-PD-1 antibody. T-lymphocyte-cytotoxicity, flow cytometric analysis, immunohistochemical, immunofluorescence staining, CD8+ -T cell apoptosis and enzyme-linked immunosorbent assays were performed to evaluate the efficacy of combination therapy with anchored-GM-CSF vaccine and PD-1 blockade and to explore the related mechanism. Results: Anchored-GM-CSF vaccine could significantly increase the number of mature DCs and up-regulate PD-L1 expression dependent on IFN-γ released from CD8+ T cells. Anchored-GM-CSF vaccine combined with anti-PD-1 antibody could effectively inhibit tumor growth and even cause regression of the established tumor. More CD4+ and CD8+ T cells appeared at tumor sites and in peripheral blood in the combination therapy group than in the control groups. Splenocytes from mice of the combination therapy group exhibited the most potent cytotoxicity to MB49 cells. Apoptotic assays showed that PD-1 blockade could significantly reduce CD8+ T cells apoptosis. Conclusions: Anchored-GM-CSF vaccines and anti-PD-1 antibodies have synergistic effects in metastatic bladder cancer treatment. PD-1 blockade can overcome immune resistance in treatment with the Anchored-GM-CSF vaccine, while Anchored-GM-CSF vaccine can enhance the efficacy of PD-1 blockade therapy.

References Powered by Scopus

The blockade of immune checkpoints in cancer immunotherapy

11047Citations
N/AReaders
Get full text

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

4261Citations
N/AReaders
Get full text

Restoring function in exhausted CD8 T cells during chronic viral infection

3361Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1

78Citations
N/AReaders
Get full text

Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer

23Citations
N/AReaders
Get full text

Inclusion of PD-L1 into a recombinant profilin antigen enhances immunity against Babesia microti in a murine model

3Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Zhang, X., Shi, X., Li, J., Mo, L., Hu, Z., Gao, J., … Long, Z. (2018). PD-1 blockade overcomes adaptive immune resistance in treatment with anchored-GM-CSF bladder cancer cells vaccine. Journal of Cancer, 9(23), 4374–4381. https://doi.org/10.7150/jca.25423

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

67%

Researcher 2

17%

Professor / Associate Prof. 1

8%

Lecturer / Post doc 1

8%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 5

38%

Medicine and Dentistry 3

23%

Immunology and Microbiology 3

23%

Agricultural and Biological Sciences 2

15%

Save time finding and organizing research with Mendeley

Sign up for free